Navigation Links
GLEEVEC - An Oral treatment for leukemia

The U.S.Food and Drug Administration (FDA) at a conference in Washington, approves the new leukemia drug-GLEEVEC, first of its kind that directly removes the sign of a protein known to cause cancer. It is given as an oral treatment for chronic myelogenous leukemia (CML). Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Gleevec, was discovered and developed by Novartis Oncology in collaboration with its colleagues. CML is a disease in which too many white blood cells are produced in the bone marrow. In the early stages of CML, most patients do not have any symptoms of cancer,but the disease progresses slowly.

In the chronic phase, bone marrow transplantation is the only known cure. But there are many problems and side effects regarding the tranplantation which makes it more difficult to perform.

Gleevec has produced higher remission rates in comparison to the drug-interferon alfa, in three short-duration, early phase clinical trials.After many clinical trials - the FDA approved Gleevec.

Richard Klausner, M.D., director of the National Cancer Institute, said that he shared in the excitement of people with CML, but he also mentioned several caveats. He said many research questions remain to be answered, such as how long Gleevec will control CML. Does the drug actually cure CML patients? Or, does it delay the onset of moreadvanced forms of the cancer?

According to Klausner, "Gleevec offers proof that molecular targeting works in treating cancer, provided that the target is correctly chosen. The challenge now is to find these targets."

Courtesy: Novartis Oncology
'"/>




Page: 1

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. Thyroid hormone treatment hastens recovery after cardiac surgery
3. Feeding channel created by malaria parasite - a new target for malaria treatments
4. Now umbilical cord helps in stroke treatment.
5. Now AIDS treatment comes dirt-cheap
6. Breast cancer treatment to be determined by gene test
7. Hemopurifier may revolutionise AIDS treatment
8. New drug helps boost cancer treatment
9. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology: